甘氨双唑钠联合放疗治疗原发性食管癌的评价

发布时间：2018-04-24 21:38

本文选题：甘氨双唑钠 + 食管癌　；参考：《中国临床药理学杂志》2017年23期

【摘要】：目的系统评价甘氨双唑钠联合放疗治疗原发性食管癌的有效性和安全性。方法检索EMbase,Pub Med,Cochrane Library,维普数据库、相关期刊论文、万方数据库,纳入甘氨双唑钠联合放疗对比单纯放疗治疗原发性食管癌患者的随机对照试验。试验组予以甘氨双唑钠联合放射疗法治疗,对照组予以单纯的放射疗法。用Rev Man 5.3软件对完全缓解率、总缓解率、药物不良反应发生率进行Meta分析。结果共纳入9项随机对照试验,854例受试对象,其中试验组450例,对照组404例。试验组和对照组的完全缓解率分别为54.22%(244例/450例)和28.46%(115例/404例),总缓解率分别为96.44%(434例/450例)和80.41%(324例/404例),差异均有统计学意义(均P0.05)。试验组和对照组的药物不良反应发生率分别为49.42%(86例/174例)和55.83%(67例/120例),差异无统计学意义(P0.05)。结论甘氨双唑钠联合放疗治疗原发性食管癌的临床疗效显著优于单纯放疗。
[Abstract]:Objective to evaluate the efficacy and safety of gallidiazole sodium combined with radiotherapy in the treatment of primary esophageal carcinoma. Methods We searched EMbase Pub MedCochrane Library, Weip Database, Chinese Journal Full-text Database and Wanfang Database, and conducted a randomized controlled trial in combination with radiotherapy and radiotherapy in patients with primary esophageal cancer. The experimental group was treated with glymediazole sodium combined with radiotherapy, while the control group was treated with radiotherapy alone. The complete remission rate, total remission rate and incidence rate of adverse drug reactions were analyzed by Meta with Rev Man 5.3 software. Results A total of 854 subjects were included in 9 randomized controlled trials, including 450 cases in the trial group and 404 cases in the control group. The complete remission rates of the trial group and the control group were 54.22 ~ 244 / / 450 and 28.46 / 115 / / 404, respectively. The total remission rate was 96.4444 / 434 / / 450) and 80.41 / 324 / 404 / 404, respectively. The difference was statistically significant (all P 0.05). The incidence of adverse drug reactions in the trial group and the control group was 49.42 / 86 and 55.83 / 67 / 120, respectively. There was no significant difference between the two groups (P 0.05). Conclusion the clinical curative effect of combined radiotherapy with glycidizole sodium is better than that of radiotherapy alone in the treatment of primary esophageal carcinoma.
【作者单位】：首都医科大学附属北京天坛医院药学部;北京丰台区南苑社区卫生服务中心药剂科;
【分类号】：R735.1

【相似文献】